MX2022011488A - Método para tratar infecciones virales con monosacáridos tipo hexosa y análogos de los mismos. - Google Patents

Método para tratar infecciones virales con monosacáridos tipo hexosa y análogos de los mismos.

Info

Publication number
MX2022011488A
MX2022011488A MX2022011488A MX2022011488A MX2022011488A MX 2022011488 A MX2022011488 A MX 2022011488A MX 2022011488 A MX2022011488 A MX 2022011488A MX 2022011488 A MX2022011488 A MX 2022011488A MX 2022011488 A MX2022011488 A MX 2022011488A
Authority
MX
Mexico
Prior art keywords
analogs
viral infections
treating viral
monosaccharides
hexose
Prior art date
Application number
MX2022011488A
Other languages
English (en)
Spanish (es)
Inventor
Donald Picker
Walter Klemp
Rafal Zielinski
Waldemar Priebe
Izabela Fokt
Stanislaw Skora
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Publication of MX2022011488A publication Critical patent/MX2022011488A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004Monosaccharides having only carbon, hydrogen and oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024Esters of saccharides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
MX2022011488A 2020-03-16 2021-03-16 Método para tratar infecciones virales con monosacáridos tipo hexosa y análogos de los mismos. MX2022011488A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062990337P 2020-03-16 2020-03-16
PCT/US2021/022622 WO2021188586A1 (en) 2020-03-16 2021-03-16 Method of treating viral infections with hexose type monosaccharides and analogs thereof

Publications (1)

Publication Number Publication Date
MX2022011488A true MX2022011488A (es) 2023-03-01

Family

ID=75439533

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022011488A MX2022011488A (es) 2020-03-16 2021-03-16 Método para tratar infecciones virales con monosacáridos tipo hexosa y análogos de los mismos.

Country Status (11)

Country Link
US (1) US20230130134A1 (https=)
EP (1) EP4121060A1 (https=)
JP (1) JP2023518249A (https=)
KR (1) KR20220166800A (https=)
CN (1) CN115515601A (https=)
AU (1) AU2021239927A1 (https=)
BR (1) BR112022018536A2 (https=)
CA (1) CA3170872A1 (https=)
IL (1) IL296389A (https=)
MX (1) MX2022011488A (https=)
WO (1) WO2021188586A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024118503A1 (en) 2022-11-28 2024-06-06 Hongene Biotech Corporation Functionalized n-acetylgalactosamine analogs
EP4582080A1 (en) 2024-01-02 2025-07-09 G.ST Antivirals GmbH Dispenser for mucosal administration comprising 2-deoxy-glucose or analogues thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6670330B1 (en) 2000-05-01 2003-12-30 Theodore J. Lampidis Cancer chemotherapy with 2-deoxy-D-glucose
WO2004007747A2 (en) * 2002-07-12 2004-01-22 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Assays for assembly of ebola virus nucleocapsids
WO2004062604A2 (en) 2003-01-10 2004-07-29 Threshold Pharmaceuticals, Inc. Treatment of cancer with 2-deoxyglucose
BRPI0708273A2 (pt) * 2006-02-24 2011-05-24 Univ Texas uso de compostos de hexoses
WO2009108926A1 (en) 2008-02-29 2009-09-03 Board Of Regents, The University Of Texas System Inhibitors of glycolysis useful in the treatment of brain tumors
WO2008131024A1 (en) 2007-04-17 2008-10-30 Board Of Regents, The University Of Texas System Iodo-hexose compounds useful to treat cancer
ES2628180T3 (es) 2008-07-11 2017-08-02 Board Of Regents, The University Of Texas System Nuevos acetatos de 2-desoxi monosacáridos con actividad anticancerosa
WO2010115184A2 (en) * 2009-04-03 2010-10-07 Achillion Pharmaceuticals, Inc. Hydroxythienoquinolones and related compounds as anti-infective agents
WO2012097052A2 (en) * 2011-01-11 2012-07-19 Intertech Bio, Llc Monosaccharide-based compounds for the treatment of proliferative and inflammatory dermatological diseases
EP3517117A1 (en) * 2018-01-30 2019-07-31 Medizinische Universität Wien Medicament for prevention or treatment of rhinovirus infection

Also Published As

Publication number Publication date
AU2021239927A1 (en) 2022-10-06
BR112022018536A2 (pt) 2022-11-29
KR20220166800A (ko) 2022-12-19
CN115515601A (zh) 2022-12-23
JP2023518249A (ja) 2023-04-28
IL296389A (en) 2022-11-01
EP4121060A1 (en) 2023-01-25
CA3170872A1 (en) 2021-09-23
WO2021188586A1 (en) 2021-09-23
US20230130134A1 (en) 2023-04-27

Similar Documents

Publication Publication Date Title
Mehrzadi et al. SARS-CoV-2 and other coronaviruses negatively influence mitochondrial quality control: beneficial effects of melatonin
MX2022011488A (es) Método para tratar infecciones virales con monosacáridos tipo hexosa y análogos de los mismos.
Morandini et al. The role of P2X7 receptor in infectious inflammatory diseases and the influence of ectonucleotidases
CL2020001146A1 (es) Nuevas indol-2-carboxamidas sustituidas con pirazolopiperidina, de alta actividad, activas contra el virus de la hepatitis b (vhb).
MX2022012424A (es) Tratamiento del sindrome del cromosoma x fragil con canabidiol.
CL2020001145A1 (es) Nuevas indol-2-carboxamidas sustituidas con amino-tiazol, de alta actividad, activas contra el virus de la hepatitis b (vhb).
BR112016022976A8 (pt) métodos para o tratamento de hcv
UY38434A (es) Nuevas 6,7-dihidro-4h-pirazolo[1,5-a]pirazin indol-2-carboxamidas activas contra el virus de la hepatitis b (hbv)
BR112018071997A2 (pt) nanopartícula de quitosana-rna, nanopartícula de quitosana-dsrna, composição nutracêutica, crustáceo criado em cativeiro, e método de tratamento ou prevenção de uma doença ou condição em um crustáceo criado em cativeiro associado a um vírus patogênico
ZA202207169B (en) Methods, compositions, and vaccines for treating a virus infection
MX2021005967A (es) Formas purificadas de rofecoxib, métodos de fabricación y uso.
AR118850A1 (es) Composiciones útiles en el tratamiento de leucodistrofia metacromática
BR112015020918A2 (pt) métodos para tratar o hcv
ECSP21031085A (es) Nuevas 6,7-dihidro-4h-pirazolo[1,5-a] pirazinindol-2-carboxamidas activas contra el virus de la hepatitis b (vhb)
BR112018068342A2 (pt) vacina de vírus zika vivo atenuado
BR112022003659A2 (pt) Composições e métodos de tratamento de doenças vasculares
BR112018000383A2 (pt) métodos para tratar hcv
MX2021006993A (es) Analogos de nucleosidos de ciclopentilo como antivirales.
WO2020055547A3 (en) Methods and compositions for honey bee health
MX2022000232A (es) Composiciones y metodos para tratar o evitar infecciones oculares con filociclovir.
MX2020002156A (es) Composiciones y metodos para el uso anti viral de analogos y mimeticos de lisina sintetica.
UY39172A (es) Análogos de nucleósido bi- y monocíclicos para el tratamiento de la hepatitis e
MX2022004799A (es) Composiciones y metodos para el tratamiento de los trastornos de almacenamiento de glucogeno.
CO2017007689A2 (es) Composiciones y métodos que utilizan il-8 para aumentar la producción de leche y mejorar la salud reproductiva e inhibir la hipercetonemia en mamíferos
MX2021015441A (es) Formas cristalinas de cabotegravir de sodio.